DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Vincristine (Vincristine) - Diarrhoea - Suspected Cause - Side Effect Reports

 
 



Index of reports > Cases with Diarrhoea (71)

Below is the selection of side effect reports (a.k.a. adverse event reports) related to Vincristine where reactions include diarrhoea. The selected reports were submitted to the FDA during the sample period of about a year.

 Reports 1 - 30 of 71   Next >>

Possible Vincristine side effects in

Reported by a physician from United States on 2012-08-22

Patient:

Reactions: Abdominal Pain, Thrombosis, Hyperkalaemia, Coagulopathy, Hypoglycaemia, Hypocalcaemia, Hypoxia, Hiccups, Alanine Aminotransferase Abnormal, Pneumonitis, Cough, Pain in Extremity, Hypotension, Hyperglycaemia, External Ear Pain, Haematotoxicity, Dehydration, Lower Gastrointestinal Haemorrhage, Hypofibrinogenaemia, Aspartate Aminotransferase Abnormal, Hypokalaemia, Blood Bilirubin Abnormal, Pleural Effusion, Decreased Appetite, Gamma-Glutamyltransferase Abnormal, Hyponatraemia, Hypercalcaemia, Hypophosphataemia, Diarrhoea, Hypoalbuminaemia, Hypertension, Infection

Adverse event resulted in: hospitalization

Drug(s) suspected as cause:
Asparaginase
    Dosage: 2500 units/m2/dose as 4 weekly doses
    Indication: Acute Lymphocytic Leukaemia

Bortezomib
    Dosage: 1.3 mg/sq.m/dose on days 1, 4, 8 and 11 combined with vxld
    Indication: Acute Lymphocytic Leukaemia

Cytarabine
    Dosage: on day 1 for all patients and on days 8, 15, 22 for cns invlovment
    Indication: Acute Lymphocytic Leukaemia

Dexamethasone
    Dosage: 10 mg/m2/day divided in to 2 doses for 14 consecutive days
    Administration route: Oral
    Indication: Acute Lymphocytic Leukaemia

Doxorubicin HCL
    Dosage: given over 15-30 minutes on day 1
    Indication: Acute Lymphocytic Leukaemia

Hydrocortisone
    Dosage: on days 8, 15 and 22
    Indication: Acute Lymphocytic Leukaemia

Methotrexate Sodium
    Dosage: 1 dose on day 15 for no cns involvement and on days 8, 15, 22 for cns involvement
    Indication: Acute Lymphocytic Leukaemia

Vincristine
    Dosage: 1.5 mg/m2/dose, max. 2 mg, by push on days 1, 8, 15 and 22
    Indication: Acute Lymphocytic Leukaemia

Other drugs received by patient: Vancomycin; Posaconazole; Voriconazole; Levofloxacin



Possible Vincristine side effects in

Reported by a physician from United States on 2012-08-20

Patient:

Reactions: Abdominal Pain, Thrombosis, Hyperkalaemia, Hypoglycaemia, Coagulopathy, Hypokalaemia, Blood Bilirubin Abnormal, Hiccups, Pleural Effusion, Hypoxia, Hypocalcaemia, Alanine Aminotransferase Abnormal, Cough, Pneumonitis, Decreased Appetite, Pain in Extremity, Hypotension, Hyperglycaemia, Gamma-Glutamyltransferase Abnormal, Hyponatraemia, External Ear Pain, Hypercalcaemia, Haematotoxicity, Hypophosphataemia, Diarrhoea, Dehydration, Hypoalbuminaemia, Lower Gastrointestinal Haemorrhage, Hypertension, Hypofibrinogenaemia, Aspartate Aminotransferase Abnormal, Infection

Adverse event resulted in: hospitalization

Drug(s) suspected as cause:
Asparaginase
    Dosage: 2500 units/m2/dose as 4 weekly doses
    Indication: Acute Lymphocytic Leukaemia

Bortezomib
    Dosage: 1.3 mg/sq.m/dose on days 1, 4, 8 and 11 combined with vxld
    Indication: Acute Lymphocytic Leukaemia

Cytarabine
    Dosage: on day 1 for all patients and on days 8, 15, 22 for cns invlovment
    Indication: Acute Lymphocytic Leukaemia

Dexamethasone
    Dosage: 10 mg/m2/day divided in to 2 doses for 14 consecutive days
    Administration route: Oral
    Indication: Acute Lymphocytic Leukaemia

Doxorubicin Hydrochloride
    Dosage: given over 15-30 minutes on day 1
    Indication: Acute Lymphocytic Leukaemia

Hydrocortisone
    Dosage: on days 8, 15 and 22
    Indication: Acute Lymphocytic Leukaemia

Methotrexate
    Dosage: 1 dose on day 15 for no cns involvement and on days 8, 15, 22 for cns involvement
    Indication: Acute Lymphocytic Leukaemia

Vincristine
    Dosage: 1.5 mg/m2/dose, max. 2 mg, by push on days 1, 8, 15 and 22
    Indication: Acute Lymphocytic Leukaemia

Other drugs received by patient: Levofloxacin; Voriconazole; Posaconazole; Vancomycin



Possible Vincristine side effects in male

Reported by a physician from India on 2012-08-17

Patient: male, weighing 65.0 kg (143.0 pounds)

Reactions: Diarrhoea, Febrile Neutropenia

Adverse event resulted in: hospitalization

Drug(s) suspected as cause:
Blinded Gp2013
    Dosage: code not broken
    Indication: non-Hodgkin's Lymphoma
    Start date: 2012-08-06

Blinded Mabthera
    Dosage: code not broken
    Indication: non-Hodgkin's Lymphoma
    Start date: 2012-08-06

Blinded NO Treatment Received
    Dosage: code not broken
    Indication: non-Hodgkin's Lymphoma
    Start date: 2012-08-06

Cyclophosphamide
    Indication: non-Hodgkin's Lymphoma

Prednisone TAB
    Administration route: Oral
    Indication: non-Hodgkin's Lymphoma

Vincristine
    Indication: non-Hodgkin's Lymphoma



Possible Vincristine side effects in

Reported by a physician from United States on 2012-08-16

Patient:

Reactions: Nausea, Pain, Motor Dysfunction, Rash, Peripheral Sensory Neuropathy, Fatigue, Blood Potassium Decreased, Dyspepsia, Diarrhoea, Neutropenia, Thrombocytopenia

Drug(s) suspected as cause:
Cyclophosphamide
    Dosage: on day 1

Cyclophosphamide
    Dosage: on day 1
    Indication: Lymphocytic Lymphoma

Cyclophosphamide
    Dosage: on day 1
    Indication: non-Hodgkin's Lymphoma

Cyclophosphamide
    Dosage: on day 1
    Indication: B-Cell Lymphoma

Cyclophosphamide
    Dosage: on day 1
    Indication: Lymphoma

Cyclophosphamide
    Dosage: on day 1
    Indication: Waldenstrom's Macroglobulinaemia

Doxorubicin HCL
    Dosage: on day 1
    Indication: non-Hodgkin's Lymphoma

Doxorubicin HCL
    Dosage: on day 1

Doxorubicin HCL
    Dosage: on day 1

Doxorubicin HCL
    Dosage: on day 1
    Indication: Lymphoma

Doxorubicin HCL
    Dosage: on day 1

Doxorubicin HCL
    Dosage: on day 1
    Indication: Waldenstrom's Macroglobulinaemia

Doxorubicin HCL
    Dosage: on day 1
    Indication: B-Cell Lymphoma

Doxorubicin HCL
    Dosage: on day 1

Doxorubicin HCL
    Dosage: on day 1
    Indication: Lymphocytic Lymphoma

Doxorubicin HCL
    Dosage: on day 1

Doxorubicin HCL
    Dosage: on day 1

Doxorubicin HCL
    Dosage: on day 1

Prednisone TAB
    Dosage: on days 1-5
    Administration route: Oral
    Indication: B-Cell Lymphoma

Prednisone TAB
    Dosage: on days 1-5
    Administration route: Oral
    Indication: Waldenstrom's Macroglobulinaemia

Prednisone TAB
    Dosage: on days 1-5
    Administration route: Oral
    Indication: non-Hodgkin's Lymphoma

Prednisone TAB
    Dosage: on days 1-5
    Administration route: Oral

Prednisone TAB
    Dosage: on days 1-5
    Administration route: Oral
    Indication: Lymphoma

Prednisone TAB
    Dosage: on days 1-5
    Administration route: Oral
    Indication: Lymphocytic Lymphoma

Rituximab
    Dosage: on day 1
    Indication: Waldenstrom's Macroglobulinaemia

Rituximab
    Dosage: on day 1

Rituximab
    Dosage: maintenance

Rituximab
    Dosage: on day 1

Rituximab
    Dosage: maintenance
    Indication: Lymphocytic Lymphoma

Rituximab
    Dosage: maintenance
    Indication: B-Cell Lymphoma

Rituximab
    Dosage: on day 1

Rituximab
    Dosage: maintenance
    Indication: non-Hodgkin's Lymphoma

Rituximab
    Dosage: on day 1

Rituximab
    Dosage: maintenance

Rituximab
    Dosage: maintenance
    Indication: Lymphoma

Rituximab
    Dosage: on day 1

Velcade
    Dosage: for every 6 months for 2 years or till progressive disease (maintenance)

Velcade
    Dosage: 1.0 to 1.6 mg/m2 on days 1 and 8
    Indication: B-Cell Lymphoma

Velcade
    Dosage: 1.0 to 1.6 mg/m2 on days 1 and 8

Velcade
    Dosage: for every 6 months for 2 years or till progressive disease (maintenance)

Velcade
    Dosage: for every 6 months for 2 years or till progressive disease (maintenance)

Velcade
    Dosage: 1.0 to 1.6 mg/m2 on days 1 and 8
    Indication: Lymphoma

Velcade
    Dosage: 1.0 to 1.6 mg/m2 on days 1 and 8
    Indication: Waldenstrom's Macroglobulinaemia

Velcade
    Dosage: 1.0 to 1.6 mg/m2 on days 1 and 8

Velcade
    Dosage: 1.0 to 1.6 mg/m2 on days 1 and 8

Velcade
    Dosage: for every 6 months for 2 years or till progressive disease (maintenance)

Velcade
    Dosage: for every 6 months for 2 years or till progressive disease (maintenance)
    Indication: Lymphocytic Lymphoma

Velcade
    Dosage: for every 6 months for 2 years or till progressive disease (maintenance)
    Indication: non-Hodgkin's Lymphoma

Vincristine
    Dosage: on day 1 not to exceed 1.5 mg from level 1 and 2 and not to exceed 2 mg for level 3
    Indication: non-Hodgkin's Lymphoma

Vincristine
    Dosage: on day 1 not to exceed 1.5 mg from level 1 and 2 and not to exceed 2 mg for level 3

Vincristine
    Dosage: on day 1 not to exceed 1.5 mg from level 1 and 2 and not to exceed 2 mg for level 3
    Indication: Waldenstrom's Macroglobulinaemia

Vincristine
    Dosage: on day 1 not to exceed 1.5 mg from level 1 and 2 and not to exceed 2 mg for level 3
    Indication: Lymphoma

Vincristine
    Dosage: on day 1 not to exceed 1.5 mg from level 1 and 2 and not to exceed 2 mg for level 3
    Indication: B-Cell Lymphoma

Vincristine
    Dosage: on day 1 not to exceed 1.5 mg from level 1 and 2 and not to exceed 2 mg for level 3
    Indication: Lymphocytic Lymphoma

Other drugs received by patient: Acetaminophen; Diphenhydramine Hydrochloride; Ondansetron



Possible Vincristine side effects in

Reported by a physician from United States on 2012-08-14

Patient:

Reactions: Thrombosis, Abdominal Pain, Hyperkalaemia, Hypoglycaemia, Coagulopathy, Hypoxia, Hypocalcaemia, Hiccups, Alanine Aminotransferase Abnormal, Cough, Pneumonitis, Pain in Extremity, Hyperglycaemia, Hypotension, External Ear Pain, Haematotoxicity, Dehydration, Lower Gastrointestinal Haemorrhage, Hypofibrinogenaemia, Aspartate Aminotransferase Abnormal, Hypokalaemia, Neuropathy Peripheral, Blood Bilirubin Abnormal, Pleural Effusion, Decreased Appetite, Hyponatraemia, Gamma-Glutamyltransferase Abnormal, Hypercalcaemia, Hypophosphataemia, Diarrhoea, Hypoalbuminaemia, Hypertension, Infection

Adverse event resulted in: hospitalization

Drug(s) suspected as cause:
Asparaginase
    Dosage: 2500 units/m2/dose as 4 weekly doses
    Indication: Acute Lymphocytic Leukaemia

Bortezomib
    Dosage: 1.3 mg/sq.m/dose on days 1, 4, 8 and 11 combined with vxld
    Indication: Acute Lymphocytic Leukaemia

Cytarabine
    Dosage: on day 1 for all patients and on days 8, 15, 22 for cns invlovment
    Indication: Acute Lymphocytic Leukaemia

Dexamethasone
    Dosage: 10 mg/m2/day divided in to 2 doses for 14 consecutive days
    Administration route: Oral
    Indication: Acute Lymphocytic Leukaemia

Doxorubicin Hydrochloride
    Dosage: given over 15-30 minutes on day 1
    Indication: Acute Lymphocytic Leukaemia

Hydrocortisone
    Dosage: on days 8, 15 and 22
    Indication: Acute Lymphocytic Leukaemia

Methotrexate
    Dosage: 1 dose on day 15 for no cns involvement and on days 8, 15, 22 for cns involvement
    Indication: Acute Lymphocytic Leukaemia

Vincristine
    Dosage: 1.5 mg/m2/dose, max. 2 mg, by push on days 1, 8, 15 and 22
    Indication: Acute Lymphocytic Leukaemia

Other drugs received by patient: Levofloxacin; Vancomycin; Posaconazole; Voriconazole



Possible Vincristine side effects in

Reported by a physician from United Kingdom on 2012-08-10

Patient:

Reactions: Diarrhoea, Anaemia, Dizziness, Pulmonary Mycosis, Lethargy

Adverse event resulted in: hospitalization

Drug(s) suspected as cause:
Cyclophosphamide
    Dosage: 1500 mg, unk
    Indication: Diffuse Large B-Cell Lymphoma
    Start date: 2012-04-03
    End date: 2012-07-04

Doxorubicin HCL
    Dosage: 100 mg, unk
    Indication: Diffuse Large B-Cell Lymphoma
    Start date: 2012-04-03
    End date: 2012-07-04

Prednisolone
    Dosage: 100 mg, unk
    Indication: Diffuse Large B-Cell Lymphoma
    Start date: 2012-04-03
    End date: 2012-07-08

Rituximab
    Dosage: 750 mg, unk
    Indication: Diffuse Large B-Cell Lymphoma
    Start date: 2012-04-03
    End date: 2012-07-04

Velcade
    Dosage: 2.6 mg, unk
    Indication: Diffuse Large B-Cell Lymphoma
    Start date: 2012-04-03
    End date: 2012-07-04

Vincristine
    Dosage: 2 mg, unk
    Indication: Diffuse Large B-Cell Lymphoma
    Start date: 2012-04-03
    End date: 2012-07-04

Other drugs received by patient: Prednisolone; Tramadol HCL; Chlorhexidine Gluconate; Omeprazole; Itraconazole; Acyclovir; Symbicort; Montelukast; Cetraben / 01561901 /; Fluconazole; Nitrofurantoin; Citalopram Hydrobromide; NEO-Mercazole TAB; Cotrim; Ferrous Fumarate; Ventolin; Enoxaparin Sodium; Metoclopramide



Possible Vincristine side effects in 46 year old female

Reported by a individual with unspecified qualification from United States on 2012-08-08

Patient: 46 year old female

Reactions: Dyspnoea, Pain in Extremity, Myelodysplastic Syndrome, General Physical Health Deterioration, Pyrexia, Pulmonary Haemorrhage, Zygomycosis, Diarrhoea, Skin Discolouration, Central Nervous System Infection, Small Intestinal Haemorrhage, Cough

Adverse event resulted in: death

Drug(s) suspected as cause:
Carmustine
    Indication: Diffuse Large B-Cell Lymphoma

Carmustine
    Indication: Diffuse Large B-Cell Lymphoma

Cyclophosphamide
    Dosage: 400 ug, intravenous, every two months
    Indication: Diffuse Large B-Cell Lymphoma

Cytarabine
    Indication: Diffuse Large B-Cell Lymphoma

Doxorubicin HCL
    Indication: Diffuse Large B-Cell Lymphoma

Idarubicin Hydrochloride
    Indication: Diffuse Large B-Cell Lymphoma

Melphalan (Melphalan) (Melphalen)
    Indication: Diffuse Large B-Cell Lymphoma

Melphalan Hydrochloride
    Indication: Diffuse Large B-Cell Lymphoma

Rituximab (Rituximab) (Rituximab)
    Indication: Diffuse Large B-Cell Lymphoma

Rituximab (Rituximab) (Rituximab)
    Indication: Diffuse Large B-Cell Lymphoma

Vincristine
    Indication: Diffuse Large B-Cell Lymphoma

Vincristine
    Indication: Diffuse Large B-Cell Lymphoma



Possible Vincristine side effects in 41 year old male

Reported by a physician from Canada on 2012-08-03

Patient: 41 year old male

Reactions: Ecthyma, Diarrhoea, Pseudomonas Infection, Febrile Neutropenia

Adverse event resulted in: hospitalization

Drug(s) suspected as cause:
Cyclophosphamide
    Indication: B-Cell Lymphoma Stage IV

Doxorubicin HCL
    Indication: B-Cell Lymphoma Stage IV

Prednisone
    Indication: B-Cell Lymphoma Stage IV

Rituximab
    Indication: B-Cell Lymphoma Stage IV

Vincristine
    Indication: B-Cell Lymphoma Stage IV

Other drugs received by patient: Epogen; Enoxaparin Sodium; Filgrastim



Possible Vincristine side effects in

Reported by a physician from United States on 2012-08-01

Patient:

Reactions: Nausea, Motor Dysfunction, Pain, Rash, Peripheral Sensory Neuropathy, Fatigue, Dyspepsia, Blood Potassium Decreased, Diarrhoea, Neutropenia, Thrombocytopenia

Drug(s) suspected as cause:
Cyclophosphamide
    Dosage: on day 1
    Indication: Waldenstrom's Macroglobulinaemia

Cyclophosphamide
    Dosage: on day 1
    Indication: B-Cell Lymphoma

Cyclophosphamide
    Dosage: on day 1
    Indication: Lymphoma

Cyclophosphamide
    Dosage: on day 1
    Indication: non-Hodgkin's Lymphoma

Cyclophosphamide
    Dosage: on day 1
    Indication: Lymphocytic Lymphoma

Cyclophosphamide
    Dosage: on day 1

Doxorubicin Hydrochloride
    Dosage: on day 1
    Indication: Waldenstrom's Macroglobulinaemia

Doxorubicin Hydrochloride
    Dosage: on day 1
    Indication: Lymphoma

Doxorubicin Hydrochloride
    Dosage: on day 1
    Indication: non-Hodgkin's Lymphoma

Doxorubicin Hydrochloride
    Dosage: on day 1
    Indication: Lymphocytic Lymphoma

Doxorubicin Hydrochloride
    Dosage: on day 1

Doxorubicin Hydrochloride
    Dosage: on day 1
    Indication: B-Cell Lymphoma

Prednisone
    Dosage: on days 1-5
    Administration route: Oral
    Indication: Lymphoma

Prednisone
    Dosage: on days 1-5
    Administration route: Oral
    Indication: B-Cell Lymphoma

Prednisone
    Dosage: on days 1-5
    Administration route: Oral
    Indication: Waldenstrom's Macroglobulinaemia

Prednisone
    Dosage: on days 1-5
    Administration route: Oral
    Indication: Lymphocytic Lymphoma

Prednisone
    Dosage: on days 1-5
    Administration route: Oral

Prednisone
    Dosage: on days 1-5
    Administration route: Oral
    Indication: non-Hodgkin's Lymphoma

Rituximab
    Dosage: maintenance
    Indication: Waldenstrom's Macroglobulinaemia

Rituximab
    Dosage: maintenance

Rituximab
    Dosage: on day 1
    Indication: Lymphocytic Lymphoma

Rituximab
    Dosage: maintenance

Rituximab
    Dosage: on day 1

Rituximab
    Dosage: on day 1
    Indication: B-Cell Lymphoma

Rituximab
    Dosage: on day 1
    Indication: non-Hodgkin's Lymphoma

Rituximab
    Dosage: maintenance

Rituximab
    Dosage: maintenance

Rituximab
    Dosage: on day 1
    Indication: Lymphoma

Rituximab
    Dosage: maintenance

Rituximab
    Dosage: on day 1

Velcade
    Dosage: for every 6 months for 2 years or till progressive disease (maintenance)

Velcade
    Dosage: 1.0 to 1.6 mg/m2 on days 1 and 8

Velcade
    Dosage: for every 6 months for 2 years or till progressive disease (maintenance)
    Indication: non-Hodgkin's Lymphoma

Velcade
    Dosage: 1.0 to 1.6 mg/m2 on days 1 and 8
    Indication: B-Cell Lymphoma

Velcade
    Dosage: 1.0 to 1.6 mg/m2 on days 1 and 8

Velcade
    Dosage: 1.0 to 1.6 mg/m2 on days 1 and 8
    Indication: Lymphoma

Velcade
    Dosage: for every 6 months for 2 years or till progressive disease (maintenance)
    Indication: Lymphocytic Lymphoma

Velcade
    Dosage: for every 6 months for 2 years or till progressive disease (maintenance)

Velcade
    Dosage: for every 6 months for 2 years or till progressive disease (maintenance)

Velcade
    Dosage: for every 6 months for 2 years or till progressive disease (maintenance)

Velcade
    Dosage: 1.0 to 1.6 mg/m2 on days 1 and 8
    Indication: Waldenstrom's Macroglobulinaemia

Velcade
    Dosage: 1.0 to 1.6 mg/m2 on days 1 and 8

Vincristine
    Dosage: on day 1 not to exceed 1.5 mg from level 1 and 2 and not to exceed 2 mg for level 3
    Indication: Waldenstrom's Macroglobulinaemia

Vincristine
    Dosage: on day 1 not to exceed 1.5 mg from level 1 and 2 and not to exceed 2 mg for level 3
    Indication: Lymphocytic Lymphoma

Vincristine
    Dosage: on day 1 not to exceed 1.5 mg from level 1 and 2 and not to exceed 2 mg for level 3

Vincristine
    Dosage: on day 1 not to exceed 1.5 mg from level 1 and 2 and not to exceed 2 mg for level 3
    Indication: B-Cell Lymphoma

Vincristine
    Dosage: on day 1 not to exceed 1.5 mg from level 1 and 2 and not to exceed 2 mg for level 3
    Indication: non-Hodgkin's Lymphoma

Vincristine
    Dosage: on day 1 not to exceed 1.5 mg from level 1 and 2 and not to exceed 2 mg for level 3
    Indication: Lymphoma

Other drugs received by patient: Diphenhydramine HCL; Acetaminophen; Ondansetron



Possible Vincristine side effects in 17 year old female

Reported by a physician from United States on 2012-07-25

Patient: 17 year old female, weighing 47.6 kg (104.7 pounds)

Reactions: Blood Bilirubin Increased, Dysphagia, Muscular Weakness, Vocal Cord Paralysis, Cerebrovascular Accident, Caecitis, Eating Disorder, Diarrhoea, Depressed Level of Consciousness, Acute Respiratory Distress Syndrome, Sinus Tachycardia, Spinal Cord Oedema, Peripheral Motor Neuropathy, Epistaxis, Neuralgia

Adverse event resulted in: hospitalization

Drug(s) suspected as cause:
Cyclophosphamide
    Dosage: 1000mgm2 cyclic
    Indication: T-Cell Type Acute Leukaemia

Cytarabine
    Dosage: 75mgm2 cyclic
    Indication: T-Cell Type Acute Leukaemia

Dalteparin Sodium
    Indication: Product Used FOR Unknown Indication

Mercaptopurine
    Dosage: 60mgm2 cyclic
    Administration route: Oral
    Indication: T-Cell Type Acute Leukaemia

Methotrexate
    Indication: T-Cell Type Acute Leukaemia

Nelarabine
    Dosage: 650mgm2 cyclic
    Indication: T-Cell Type Acute Leukaemia
    Start date: 2012-04-13

PEG-Asparaginase
    Indication: T-Cell Type Acute Leukaemia

Vincristine
    Dosage: 1.5mgm2 cyclic
    Indication: T-Cell Type Acute Leukaemia

Other drugs received by patient: Insulin Aspart; Lansoprazole; Vancomycin; Nystatin; Piperacillin and Tazobactam; Voriconazole



Possible Vincristine side effects in 17 year old male

Reported by a health professional (non-physician/pharmacist) from Poland on 2012-07-23

Patient: 17 year old male

Reactions: Abdominal Pain, Rhabdomyolysis, Pain in Extremity, Disseminated Intravascular Coagulation, Chromaturia, Pancytopenia, Pyrexia, Renal Failure, Renal Impairment, Diarrhoea, Clostridial Infection, Septic Shock

Adverse event resulted in: death, life threatening event, hospitalization

Drug(s) suspected as cause:
Cefepime
    Indication: Pyrexia

Doxorubicin HCL
    Indication: Ewing's Sarcoma Metastatic

Etoposide
    Indication: Ewing's Sarcoma Metastatic

Ifosfamide
    Indication: Ewing's Sarcoma Metastatic

Netilmicin Sulfate
    Indication: Pyrexia

Vincristine
    Indication: Ewing's Sarcoma Metastatic



Possible Vincristine side effects in 17 year old female

Reported by a physician from United States on 2012-07-13

Patient: 17 year old female, weighing 47.6 kg (104.7 pounds)

Reactions: Blood Bilirubin Increased, Dysphagia, Muscular Weakness, Vocal Cord Paralysis, Cerebrovascular Accident, Caecitis, Eating Disorder, Diarrhoea, Depressed Level of Consciousness, Acute Respiratory Distress Syndrome, Spinal Cord Oedema, Peripheral Motor Neuropathy, Sinus Tachycardia, Neuralgia, Epistaxis

Adverse event resulted in: hospitalization

Drug(s) suspected as cause:
Cyclophosphamide
    Dosage: 1000mgm2 cyclic
    Indication: T-Cell Type Acute Leukaemia

Cytarabine
    Dosage: 75mgm2 cyclic
    Indication: T-Cell Type Acute Leukaemia

Dalteparin Sodium
    Indication: Product Used FOR Unknown Indication

Mercaptopurine
    Dosage: 60mgm2 cyclic
    Administration route: Oral
    Indication: T-Cell Type Acute Leukaemia

Methotrexate
    Indication: T-Cell Type Acute Leukaemia

Nelarabine
    Dosage: 650mgm2 cyclic
    Indication: T-Cell Type Acute Leukaemia
    Start date: 2012-04-13

PEG-Asparaginase
    Indication: T-Cell Type Acute Leukaemia

Vincristine
    Dosage: 1.5mgm2 cyclic
    Indication: T-Cell Type Acute Leukaemia

Other drugs received by patient: Insulin Aspart; Nystatin; Voriconazole; Vancomycin; Piperacillin and Tazobactam; Lansoprazole



Possible Vincristine side effects in male

Reported by a physician from Germany on 2012-07-12

Patient: male

Reactions: Stomatitis, Diarrhoea, Dehydration, Pain of Skin, Palmar-Plantar Erythrodysaesthesia Syndrome, Gastrointestinal Inflammation

Adverse event resulted in: hospitalization

Drug(s) suspected as cause:
Cyclophosphamide
    Dosage: 1640 mg, q2wk
    Indication: B-Cell Lymphoma
    Start date: 2012-04-17

Doxorubicin HCL
    Dosage: 110 mg, q2wk
    Indication: B-Cell Lymphoma
    Start date: 2012-04-17

Neulasta
    Dosage: 6 mg, unk
    Indication: B-Cell Lymphoma
    Start date: 2012-04-20

Prednisone
    Dosage: 100 mg, unk
    Indication: B-Cell Lymphoma
    Start date: 2012-04-17

Rituximab
    Dosage: 800 mg, q2wk
    Indication: B-Cell Lymphoma
    Start date: 2012-04-16

Vincristine
    Dosage: 2 mg, q2wk
    Indication: B-Cell Lymphoma
    Start date: 2012-04-17

Other drugs received by patient: Bisoprolol Fumarate; Simvastatin; Amiodarone Hydrochloride; Levothyroxine Sodium; Digitoxin TAB



Possible Vincristine side effects in 17 year old female

Reported by a physician from United States on 2012-07-09

Patient: 17 year old female, weighing 47.6 kg (104.7 pounds)

Reactions: Blood Bilirubin Increased, Dysphagia, Cerebrovascular Accident, Caecitis, Eating Disorder, Dysphonia, Diarrhoea, Acute Respiratory Distress Syndrome, Depressed Level of Consciousness, Peripheral Motor Neuropathy, Sinus Tachycardia, Epistaxis

Adverse event resulted in: hospitalization

Drug(s) suspected as cause:
Cyclophosphamide
    Dosage: 1000mgm2 cyclic
    Indication: T-Cell Type Acute Leukaemia

Cytarabine
    Dosage: 75mgm2 cyclic
    Indication: T-Cell Type Acute Leukaemia

Dalteparin Sodium
    Indication: Product Used FOR Unknown Indication

Mercaptopurine
    Dosage: 60mgm2 cyclic
    Administration route: Oral
    Indication: T-Cell Type Acute Leukaemia

Methotrexate
    Indication: T-Cell Type Acute Leukaemia

Nelarabine
    Dosage: 650mgm2 cyclic
    Indication: T-Cell Type Acute Leukaemia
    Start date: 2012-04-13

PEG-Asparaginase
    Indication: T-Cell Type Acute Leukaemia

Vincristine
    Dosage: 1.5mgm2 cyclic
    Indication: T-Cell Type Acute Leukaemia

Other drugs received by patient: Lansoprazole; Piperacillin and Tazobactam; Vancomycin; Voriconazole; Insulin Aspart; Nystatin



Possible Vincristine side effects in male

Reported by a physician from Germany on 2012-07-09

Patient: male

Reactions: Stomatitis, Diarrhoea, Pain of Skin, Dehydration, Gastrointestinal Inflammation, Palmar-Plantar Erythrodysaesthesia Syndrome

Adverse event resulted in: hospitalization

Drug(s) suspected as cause:
Cyclophosphamide
    Indication: B-Cell Lymphoma
    Start date: 2012-04-17

Cyclophosphamide
    Dosage: reduced dose
    Start date: 2012-06-05

Doxorubicin HCL
    Indication: B-Cell Lymphoma
    Start date: 2012-04-17

Doxorubicin Hydrochloride
    Dosage: reduced dose
    Start date: 2012-06-05

Mabthera
    Dosage: reduced dose
    Start date: 2012-06-05

Mabthera
    Indication: B-Cell Lymphoma
    Start date: 2012-04-16

Pegfilgrastim
    Indication: B-Cell Lymphoma
    Start date: 2012-04-20

Prednisone TAB
    Dosage: reduced dose
    Start date: 2012-06-05

Prednisone TAB
    Indication: B-Cell Lymphoma
    Start date: 2012-04-17

Vincristine
    Indication: B-Cell Lymphoma
    Start date: 2012-04-17

Vincristine
    Dosage: reduced dose
    Start date: 2012-06-05

Other drugs received by patient: Bisoprolol Fumarate; Simvastatin; Levothyroxine Sodium; Digitoxin TAB; Amiodarone HCL



Possible Vincristine side effects in

Reported by a physician from United States on 2012-07-05

Patient:

Reactions: Fatigue, Central Nervous System Haemorrhage, Erythema Multiforme, Dyspnoea, Stomatitis, Vomiting, Gastrointestinal Toxicity, Nausea, Condition Aggravated, Rash, Haematotoxicity, Pulmonary Haemorrhage, Tumour Lysis Syndrome, Diarrhoea, Respiratory Failure, Neurological Symptom, Infection

Adverse event resulted in: death

Drug(s) suspected as cause:
Cyclophosphamide
    Dosage: for 5 days in cycle 1
    Indication: Burkitt's Lymphoma

Cyclophosphamide
    Dosage: days 1-5 during cycle 3,5 and 7

Cyclophosphamide
    Dosage: for 5 days in cycle 1
    Indication: Burkitt's Leukaemia

Cyclophosphamide
    Dosage: days 1-5 during cycle 3,5 and 7

Cytarabine
    Dosage: on days 4 and 5 of cycle 2,4 and 6
    Indication: Burkitt's Leukaemia

Cytarabine
    Dosage: on days 4 and 5 of cycle 2,4 and 6
    Indication: Burkitt's Lymphoma

Dexamethasone Sodium Phosphate
    Dosage: on days 1-5 of cycle 2,4 and 6

Dexamethasone Sodium Phosphate
    Dosage: on days 1-5 of cycle 2,4 and 6

Dexamethasone Sodium Phosphate
    Dosage: on days 1-5 of cycle 3,5 and 7
    Indication: Burkitt's Leukaemia

Dexamethasone Sodium Phosphate
    Dosage: on days 1-5 of cycle 3,5 and 7
    Indication: Burkitt's Lymphoma

Doxorubicin HCL
    Dosage: on days 4 and 5 of cycle 3,5 and 7
    Indication: Burkitt's Lymphoma

Doxorubicin HCL
    Dosage: on days 4 and 5 of cycle 3,5 and 7
    Indication: Burkitt's Leukaemia

Etoposide
    Dosage: on days 4 and 5 of cycle 2,4 and 6
    Indication: Burkitt's Lymphoma

Etoposide
    Dosage: on days 4 and 5 of cycle 2,4 and 6
    Indication: Burkitt's Leukaemia

Ifosfamide
    Dosage: on days 1-5 in cycle 2,4 and 6
    Indication: Burkitt's Lymphoma

Ifosfamide
    Dosage: on days 1-5 in cycle 2,4 and 6
    Indication: Burkitt's Leukaemia

Methotrexate
    Dosage: on day 1 of cycle 3,5 and 7
    Indication: Burkitt's Lymphoma

Methotrexate
    Dosage: on day 1 of cycle 2,4 and 6
    Indication: Burkitt's Leukaemia

Methotrexate
    Dosage: on day 1 of cycle 3,5 and 7

Methotrexate
    Dosage: on day 1 of cycle 2,4 and 6

Prednisone
    Dosage: for 7 days in cycle 1
    Indication: Burkitt's Lymphoma

Prednisone
    Dosage: for 7 days in cycle 1
    Indication: Burkitt's Leukaemia

Rituximab
    Dosage: on day 8 from cycle 3 to 7

Rituximab
    Dosage: on day 8 from cycle 3 to 7

Rituximab
    Dosage: day 8 on cycle 2; doage increased to 375 mg/m2 on day 10 and 12
    Indication: Burkitt's Leukaemia

Rituximab
    Dosage: day 8 on cycle 2; doage increased to 375 mg/m2 on day 10 and 12
    Indication: Burkitt's Lymphoma

Vincristine
    Dosage: on day 1 of cycle 3,5 and 7
    Indication: Burkitt's Lymphoma

Vincristine
    Dosage: on day 1 of cycle 2,4 and 6

Vincristine
    Dosage: on day 1 of cycle 3,5 and 7

Vincristine
    Dosage: on day 1 of cycle 2,4 and 6
    Indication: Burkitt's Leukaemia

Other drugs received by patient: Filgrastim; Unknown Medication; Leucovorin Calcium



Possible Vincristine side effects in

Reported by a physician from United States on 2012-06-28

Patient:

Reactions: Fatigue, Central Nervous System Haemorrhage, Erythema Multiforme, Vomiting, Stomatitis, Dyspnoea, Gastrointestinal Toxicity, Nausea, Condition Aggravated, Rash, Haematotoxicity, Pulmonary Haemorrhage, Tumour Lysis Syndrome, Respiratory Failure, Diarrhoea, Neurological Symptom, Infection

Adverse event resulted in: death

Drug(s) suspected as cause:
Cyclophosphamide
    Dosage: days 1-5 during cycle 3,5 and 7

Cyclophosphamide
    Dosage: days 1-5 during cycle 3,5 and 7

Cyclophosphamide
    Dosage: for 5 days in cycle 1
    Indication: Burkitt's Leukaemia

Cyclophosphamide
    Dosage: for 5 days in cycle 1
    Indication: Burkitt's Lymphoma

Cytarabine
    Dosage: on days 4 and 5 of cycle 2,4 and 6
    Indication: Burkitt's Lymphoma

Cytarabine
    Dosage: on days 4 and 5 of cycle 2,4 and 6
    Indication: Burkitt's Leukaemia

Dexamethasone
    Dosage: on days 1-5 of cycle 2,4 and 6

Dexamethasone
    Dosage: on days 1-5 of cycle 2,4 and 6

Dexamethasone
    Dosage: on days 1-5 of cycle 3,5 and 7
    Indication: Burkitt's Lymphoma

Dexamethasone
    Dosage: on days 1-5 of cycle 3,5 and 7
    Indication: Burkitt's Leukaemia

Doxorubicin HCL
    Dosage: on days 4 and 5 of cycle 3,5 and 7
    Indication: Burkitt's Lymphoma

Doxorubicin HCL
    Dosage: on days 4 and 5 of cycle 3,5 and 7
    Indication: Burkitt's Leukaemia

Etoposide
    Dosage: on days 4 and 5 of cycle 2,4 and 6
    Indication: Burkitt's Leukaemia

Etoposide
    Dosage: on days 4 and 5 of cycle 2,4 and 6
    Indication: Burkitt's Lymphoma

Ifosfamide
    Dosage: on days 1-5 in cycle 2,4 and 6
    Indication: Burkitt's Lymphoma

Ifosfamide
    Dosage: on days 1-5 in cycle 2,4 and 6
    Indication: Burkitt's Leukaemia

Methotrexate
    Dosage: on day 1 of cycle 3,5 and 7
    Indication: Burkitt's Lymphoma

Methotrexate
    Dosage: on day 1 of cycle 2,4 and 6

Methotrexate
    Dosage: on day 1 of cycle 3,5 and 7

Methotrexate
    Dosage: on day 1 of cycle 2,4 and 6
    Indication: Burkitt's Leukaemia

Prednisone TAB
    Dosage: for 7 days in cycle 1
    Indication: Burkitt's Leukaemia

Prednisone TAB
    Dosage: for 7 days in cycle 1
    Indication: Burkitt's Lymphoma

Rituximab
    Dosage: on day 8 from cycle 3 to 7

Rituximab
    Dosage: day 8 on cycle 2; doage increased to 375 mg/m2 on day 10 and 12
    Indication: Burkitt's Leukaemia

Rituximab
    Dosage: day 8 on cycle 2; doage increased to 375 mg/m2 on day 10 and 12
    Indication: Burkitt's Lymphoma

Rituximab
    Dosage: on day 8 from cycle 3 to 7

Vincristine
    Dosage: on day 1 of cycle 2,4 and 6

Vincristine
    Dosage: on day 1 of cycle 2,4 and 6
    Indication: Burkitt's Leukaemia

Vincristine
    Dosage: on day 1 of cycle 3,5 and 7

Vincristine
    Dosage: on day 1 of cycle 3,5 and 7
    Indication: Burkitt's Lymphoma

Other drugs received by patient: Unknown Medication; Leucovorin Calcium; Filgrastim



Possible Vincristine side effects in

Reported by a individual with unspecified qualification from Korea, Republic of on 2012-06-26

Patient:

Reactions: Abdominal Pain, Hyperbilirubinaemia, Anaemia, Alanine Aminotransferase Increased, Febrile Neutropenia, Rash, Pyrexia, Peripheral Sensory Neuropathy, Diarrhoea, Alopecia, Aspartate Aminotransferase Increased, Neutropenia, Asthenia, Thrombocytopenia

Drug(s) suspected as cause:
Cyclophosphamide
    Dosage: given on day 1 of each cycle
    Indication: B-Cell Lymphoma

Mabthera
    Dosage: on day 1 of every cycle
    Indication: B-Cell Lymphoma

Prednisolone
    Dosage: given on days 1 to 5 of every cycle (repeated every 3 weeks)
    Administration route: Oral
    Indication: B-Cell Lymphoma

Vincristine
    Dosage: given on day 1 of every cycle; dose: 1.4 mg/m2 ( maximum 2.0 mg)
    Indication: B-Cell Lymphoma



Possible Vincristine side effects in

Reported by a health professional (non-physician/pharmacist) from United States on 2012-06-25

Patient:

Reactions: Fatigue, Central Nervous System Haemorrhage, Erythema Multiforme, Stomatitis, Vomiting, Dyspnoea, Nausea, Gastrointestinal Toxicity, Condition Aggravated, Rash, Haematotoxicity, Pulmonary Haemorrhage, Tumour Lysis Syndrome, Diarrhoea, Respiratory Failure, Neurological Symptom, Infection

Adverse event resulted in: death

Drug(s) suspected as cause:
Cyclophosphamide
    Dosage: for 5 days in cycle 1
    Indication: Burkitt's Lymphoma

Cyclophosphamide
    Dosage: days 1-5 during cycle 3,5 and 7

Cyclophosphamide
    Dosage: days 1-5 during cycle 3,5 and 7

Cyclophosphamide
    Dosage: for 5 days in cycle 1
    Indication: Burkitt's Leukaemia

Cytarabine
    Dosage: on days 4 and 5 of cycle 2,4 and 6
    Indication: Burkitt's Leukaemia

Cytarabine
    Dosage: on days 4 and 5 of cycle 2,4 and 6
    Indication: Burkitt's Lymphoma

Dexamethasone
    Dosage: on days 1-5 of cycle 3,5 and 7
    Indication: Burkitt's Lymphoma

Dexamethasone
    Dosage: on days 1-5 of cycle 2,4 and 6

Dexamethasone
    Dosage: on days 1-5 of cycle 3,5 and 7
    Indication: Burkitt's Leukaemia

Dexamethasone
    Dosage: on days 1-5 of cycle 2,4 and 6

Doxorubicin HCL
    Dosage: on days 4 and 5 of cycle 3,5 and 7
    Indication: Burkitt's Lymphoma

Doxorubicin HCL
    Dosage: on days 4 and 5 of cycle 3,5 and 7
    Indication: Burkitt's Leukaemia

Etoposide
    Dosage: on days 4 and 5 of cycle 2,4 and 6
    Indication: Burkitt's Lymphoma

Etoposide
    Dosage: on days 4 and 5 of cycle 2,4 and 6
    Indication: Burkitt's Leukaemia

Ifosfamide
    Dosage: on days 1-5 in cycle 2,4 and 6
    Indication: Burkitt's Lymphoma

Ifosfamide
    Dosage: on days 1-5 in cycle 2,4 and 6
    Indication: Burkitt's Leukaemia

Methotrexate
    Dosage: on day 1 of cycle 2,4 and 6
    Indication: Burkitt's Leukaemia

Methotrexate
    Dosage: on day 1 of cycle 3,5 and 7

Methotrexate
    Dosage: on day 1 of cycle 2,4 and 6

Methotrexate
    Dosage: on day 1 of cycle 3,5 and 7
    Indication: Burkitt's Lymphoma

Prednisone TAB
    Dosage: for 7 days in cycle 1
    Indication: Burkitt's Lymphoma

Prednisone TAB
    Dosage: for 7 days in cycle 1
    Indication: Burkitt's Leukaemia

Rituximab
    Dosage: on day 8 from cycle 3 to 7

Rituximab
    Dosage: on day 8 from cycle 3 to 7

Rituximab
    Dosage: day 8 on cycle 2; doage increased to 375 mg/m2 on day 10 and 12
    Indication: Burkitt's Leukaemia

Rituximab
    Dosage: day 8 on cycle 2; doage increased to 375 mg/m2 on day 10 and 12
    Indication: Burkitt's Lymphoma

Vincristine
    Dosage: on day 1 of cycle 2,4 and 6
    Indication: Burkitt's Leukaemia

Vincristine
    Dosage: on day 1 of cycle 2,4 and 6

Vincristine
    Dosage: on day 1 of cycle 3,5 and 7

Vincristine
    Dosage: on day 1 of cycle 3,5 and 7
    Indication: Burkitt's Lymphoma

Other drugs received by patient: Unknown Medication; Leucovorin Calcium; Filgrastim



Possible Vincristine side effects in

Reported by a health professional (non-physician/pharmacist) from United States on 2012-06-21

Patient:

Reactions: Urticaria, Pyrexia, Headache, Oropharyngeal Pain, Constipation, Polyneuropathy, Fatigue, Dyspepsia, Oedema Peripheral, Cough, Dyspnoea, Vomiting, Nausea, Rash, Dysgeusia, Diarrhoea, Alopecia, Neutropenia, Respiratory Tract Infection, Leukopenia, Infection, Infusion Related Reaction

Drug(s) suspected as cause:
Cyclophosphamide
    Indication: B-Cell Lymphoma

Doxorubicin HCL
    Indication: B-Cell Lymphoma

Ofatumumab
    Indication: B-Cell Lymphoma

Ofatumumab

Prednisone TAB
    Administration route: Oral
    Indication: B-Cell Lymphoma

Vincristine
    Indication: B-Cell Lymphoma

Other drugs received by patient: Acetaminophen; Cetirizine; Glucocorticoids



Possible Vincristine side effects in 17 year old female

Reported by a physician from United States on 2012-06-08

Patient: 17 year old female, weighing 47.6 kg (104.7 pounds)

Reactions: Blood Bilirubin Increased, Pyrexia, Caecitis, Loss of Consciousness, Oedema Peripheral, Pulmonary Oedema, Hypocalcaemia, Acute Respiratory Distress Syndrome, Melaena, Hypertriglyceridaemia, Epistaxis, Dysphagia, Anaemia, Hyperglycaemia, General Physical Health Deterioration, Eating Disorder, Tremor, Cerebral Infarction, Depressed Level of Consciousness, Neutropenia, Confusional State, Dyskinesia, Somnolence, Splenic Infarction, Hypokalaemia, Pleural Effusion, White Blood Cell Count Decreased, Cerebrovascular Accident, Ascites, Diarrhoea, Hypophagia, Hypoalbuminaemia, Sinus Tachycardia, Hypertension

Adverse event resulted in: hospitalization

Drug(s) suspected as cause:
Cyclophosphamide
    Dosage: 1000mgm2 cyclic
    Indication: T-Cell Type Acute Leukaemia

Cytarabine
    Dosage: 75mgm2 cyclic
    Indication: T-Cell Type Acute Leukaemia

Dalteparin Sodium
    Indication: Product Used FOR Unknown Indication

Mercaptopurine
    Dosage: 60mgm2 cyclic
    Administration route: Oral
    Indication: T-Cell Type Acute Leukaemia

Methotrexate
    Indication: T-Cell Type Acute Leukaemia

Nelarabine
    Dosage: 650mgm2 cyclic
    Indication: T-Cell Type Acute Leukaemia
    Start date: 2012-04-13

Oncaspar
    Indication: T-Cell Type Acute Leukaemia

Vincristine
    Dosage: 1.5mgm2 cyclic
    Indication: T-Cell Type Acute Leukaemia

Other drugs received by patient: Nystatin; Lansoprazole; Insulin Aspart; Piperacillin and Tazobactam; Vancomycin; Voriconazole



Possible Vincristine side effects in 60 year old female

Reported by a physician from United States on 2012-06-05

Patient: 60 year old female

Reactions: Diarrhoea, Dehydration, Colitis, Hypokalaemia, Hyperuricaemia

Adverse event resulted in: hospitalization

Drug(s) suspected as cause:
Methotrexate
    Indication: Acute Lymphocytic Leukaemia
    Start date: 2011-11-17

Sprycel
    Administration route: Oral
    Indication: Acute Lymphocytic Leukaemia
    Start date: 2011-11-17

Vincristine
    Indication: Acute Lymphocytic Leukaemia
    Start date: 2011-11-17



Possible Vincristine side effects in 17 year old female

Reported by a physician from United States on 2012-05-31

Patient: 17 year old female, weighing 47.6 kg (104.7 pounds)

Reactions: Blood Bilirubin Increased, Cerebrovascular Accident, Eating Disorder, Diarrhoea, Depressed Level of Consciousness, Acute Respiratory Distress Syndrome, Sinus Tachycardia, Epistaxis

Adverse event resulted in: hospitalization

Drug(s) suspected as cause:
Cyclophosphamide
    Dosage: 1000mgm2 cyclic
    Indication: T-Cell Type Acute Leukaemia

Cytarabine
    Dosage: 75mgm2 cyclic
    Indication: T-Cell Type Acute Leukaemia

Dalteparin Sodium
    Indication: Product Used FOR Unknown Indication

Mercaptopurine
    Dosage: 60mgm2 cyclic
    Administration route: Oral
    Indication: T-Cell Type Acute Leukaemia

Methotrexate
    Indication: T-Cell Type Acute Leukaemia

Nelarabine
    Dosage: 650mgm2 cyclic
    Indication: T-Cell Type Acute Leukaemia
    Start date: 2012-04-13

PEG-Asparaginase
    Indication: T-Cell Type Acute Leukaemia

Vincristine
    Dosage: 1.5mgm2 cyclic
    Indication: T-Cell Type Acute Leukaemia

Other drugs received by patient: Voriconazole; Insulin Aspart; Nystatin; Vancomycin; Lansoprazole; Piperacillin and Tazobactam



Possible Vincristine side effects in 77 year old male

Reported by a physician from Denmark on 2012-05-29

Patient: 77 year old male, weighing 97.0 kg (213.4 pounds)

Reactions: Fatigue, Malaise, Diarrhoea, Anaemia, Dizziness, Febrile Neutropenia

Adverse event resulted in: hospitalization

Drug(s) suspected as cause:
Cyclophosphamide
    Dosage: 1612 mg, unk
    Indication: Diffuse Large B-Cell Lymphoma
    Start date: 2011-03-25

Doxorubicin HCL
    Dosage: 107 mg, unk
    Indication: Diffuse Large B-Cell Lymphoma
    Start date: 2011-03-25

Neulasta
    Dosage: 6 mg, unk
    Indication: Diffuse Large B-Cell Lymphoma
    Start date: 2011-03-26

Prednisolone
    Dosage: 100 mg, unk
    Administration route: Oral
    Indication: Diffuse Large B-Cell Lymphoma
    Start date: 2011-03-25

Rituximab
    Dosage: 750 mg, unk
    Indication: Diffuse Large B-Cell Lymphoma
    Start date: 2011-03-25

Vincristine
    Dosage: 2 mg, unk
    Indication: Diffuse Large B-Cell Lymphoma
    Start date: 2011-03-25

Other drugs received by patient: Pinex; Sulphamethizole; Valacyclovir Hydrochloride; Omeprazole



Possible Vincristine side effects in

Reported by a health professional (non-physician/pharmacist) from United States on 2012-05-18

Patient:

Reactions: Urticaria, Headache, Pyrexia, Oropharyngeal Pain, Constipation, Polyneuropathy, Fatigue, Dyspepsia, Oedema Peripheral, Cough, Dyspnoea, Vomiting, Nausea, Rash, Dysgeusia, Diarrhoea, Alopecia, Neutropenia, Respiratory Tract Infection, Leukopenia, Infection, Infusion Related Reaction

Drug(s) suspected as cause:
Cyclophosphamide
    Indication: B-Cell Lymphoma

Doxorubicin HCL
    Indication: B-Cell Lymphoma

Ofatumumab
    Indication: B-Cell Lymphoma

Ofatumumab

Prednisone
    Administration route: Oral
    Indication: B-Cell Lymphoma

Vincristine
    Indication: B-Cell Lymphoma

Other drugs received by patient: Cetirizine; Acetaminophen; Glucocorticoids



Possible Vincristine side effects in 1 year old male

Reported by a physician from United States on 2012-05-14

Patient: 1 year old male, weighing 8.8 kg (19.4 pounds)

Reactions: Food Intolerance, Parainfluenzae Virus Infection, Vomiting, Lung Infection, Cytomegalovirus Viraemia, Cytomegalovirus Colitis, Pneumonia Cytomegaloviral, Respiratory Syncytial Virus Infection, Pneumocystis Jiroveci Pneumonia, Lower Respiratory Tract Infection Viral, Diarrhoea

Adverse event resulted in: death

Drug(s) suspected as cause:
Dexamethasone
    Indication: Acute Lymphocytic Leukaemia
    Start date: 2010-09-30

Lestaurtinib

Mercaptopurine
    Indication: Acute Lymphocytic Leukaemia
    Start date: 2010-09-30

Methotrexate
    Indication: Acute Lymphocytic Leukaemia
    Start date: 2010-09-30

Vincristine
    Indication: Acute Lymphocytic Leukaemia
    Start date: 2010-09-30



Possible Vincristine side effects in male

Reported by a physician from Denmark on 2012-05-11

Patient: male, weighing 97.0 kg (213.4 pounds)

Reactions: Viral Infection, Body Temperature Increased, Anaemia, Febrile Neutropenia, Pallor, Fatigue, Malaise, Dyspnoea Exertional, Diarrhoea, Dizziness

Adverse event resulted in: hospitalization

Drug(s) suspected as cause:
Cyclophosphamide
    Indication: Diffuse Large B-Cell Lymphoma
    Start date: 2011-03-25

Cyclophosphamide
    Start date: 2011-04-26
    End date: 2011-04-26

Doxorubicin Hydrochloride
    Indication: Diffuse Large B-Cell Lymphoma
    Start date: 2011-04-26
    End date: 2011-04-26

Doxorubicin Hydrochloride
    Start date: 2011-03-25

Vincristine
    Start date: 2011-04-26
    End date: 2011-04-26

Vincristine
    Indication: Diffuse Large B-Cell Lymphoma
    Start date: 2011-03-25

Other drugs received by patient: Valacyclovir Hydrochloride; Rituximab; Prednisolone; Prednisolone; Rituximab; Pinex Junior; Neulasta; Omeprazole; Sulphamethizole; Neulasta; Prednisolone



Possible Vincristine side effects in female

Reported by a individual with unspecified qualification from Denmark on 2012-05-11

Patient: female, weighing 97.0 kg (213.4 pounds)

Reactions: Viral Infection, Malaise, Diarrhoea, Anaemia, Febrile Neutropenia

Adverse event resulted in: hospitalization

Drug(s) suspected as cause:
Cyclophosphamide
    Dosage: 1612 mg, unk
    Indication: Diffuse Large B-Cell Lymphoma
    Start date: 2011-03-25

Cyclophosphamide
    Dosage: 1612 mg, unk
    Start date: 2011-04-26
    End date: 2011-04-26

Cyclophosphamide
    Dosage: dosage form: unspecified
    Start date: 2011-04-26
    End date: 2011-04-26

Cyclophosphamide
    Dosage: dosage form: unspecified
    Start date: 2011-03-25

Doxorubicin HCL
    Dosage: 107 mg, unk
    Indication: Diffuse Large B-Cell Lymphoma
    Start date: 2011-03-25

Doxorubicin HCL
    Dosage: 107 mg, unk
    Start date: 2011-04-26
    End date: 2011-04-26

Vincristine
    Dosage: dosage form: unspecified
    Start date: 2011-03-25

Vincristine
    Dosage: dosage form: unspecified
    Start date: 2011-04-26
    End date: 2011-04-26

Vincristine
    Dosage: 2 mg, unk
    Start date: 2011-04-26
    End date: 2011-04-26

Vincristine
    Dosage: 2 mg, unk
    Indication: Diffuse Large B-Cell Lymphoma
    Start date: 2011-03-25

Other drugs received by patient: Prednisone TAB; Neulasta; Omeprazole; Prednisolone; Prednisolone; Sulphamethizole; Rituximab; Prednisone TAB; Neulasta; Valaciclovir; Pinex; Prednisolone; Rituximab



Possible Vincristine side effects in 1 year old female

Reported by a physician from United States on 2012-05-10

Patient: 1 year old female, weighing 7.6 kg (16.8 pounds)

Reactions: Dyspnoea, Vomiting, Hypothermia, Nausea, Chills, Pyrexia, Peripheral Sensory Neuropathy, Sinus Bradycardia, Hypokalaemia, Diarrhoea, Ileus, Hypoalbuminaemia, Lung Infiltration, Candidiasis, Influenza Like Illness

Adverse event resulted in: hospitalization

Drug(s) suspected as cause:
Cytarabine
    Dosage: unk mg, cyclic
    Indication: B Precursor Type Acute Leukaemia
    End date: 2012-03-22

Doxorubicin HCL
    Dosage: 60 mg/m2, cyclic
    Indication: B Precursor Type Acute Leukaemia
    Start date: 2012-03-23
    End date: 2012-03-23

Prednisone TAB
    Dosage: 20 mg/m2, unk
    Administration route: Oral
    Indication: B Precursor Type Acute Leukaemia
    Start date: 2012-03-23
    End date: 2012-03-24

Velcade
    Dosage: 1.3 mg/m2, cyclic
    Indication: B Precursor Type Acute Leukaemia
    Start date: 2012-03-23
    End date: 2012-03-23

Vincristine
    Dosage: 1.5 mg/m2, cyclic
    Indication: B Precursor Type Acute Leukaemia
    Start date: 2012-03-23
    End date: 2012-03-23



Possible Vincristine side effects in 77 year old male

Reported by a physician from Denmark on 2012-04-26

Patient: 77 year old male, weighing 97.0 kg (213.4 pounds)

Reactions: Fatigue, Malaise, Diarrhoea, Anaemia, Dizziness, Febrile Neutropenia

Adverse event resulted in: hospitalization

Drug(s) suspected as cause:
Cyclophosphamide
    Dosage: 1612 mg, unk
    Indication: Diffuse Large B-Cell Lymphoma
    Start date: 2011-03-25

Doxorubicin HCL
    Dosage: 107 mg, unk
    Indication: Diffuse Large B-Cell Lymphoma
    Start date: 2011-03-25

Neulasta
    Dosage: 6 mg, unk
    Indication: Diffuse Large B-Cell Lymphoma
    Start date: 2011-03-26

Prednisolone
    Dosage: 100 mg, unk
    Administration route: Oral
    Indication: Diffuse Large B-Cell Lymphoma
    Start date: 2011-03-25

Rituximab
    Dosage: 750 mg, unk
    Indication: Diffuse Large B-Cell Lymphoma
    Start date: 2011-03-25

Vincristine
    Dosage: 2 mg, unk
    Indication: Diffuse Large B-Cell Lymphoma
    Start date: 2011-03-25

Other drugs received by patient: Sulphamethizole; Omeprazole; Pinex; Valacyclovir Hydrochloride



 Page 1   Next >>

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017